keyword
MENU ▼
Read by QxMD icon Read
search

american society of clinical oncology

keyword
https://www.readbyqxmd.com/read/27907278/radiation-therapy-for-glioblastoma-american-society-of-clinical-oncology-clinical-practice-guideline-endorsement-of-the-american-society-for-radiation-oncology-guideline
#1
Erik P Sulman, Nofisat Ismaila, Susan M Chang
No abstract text is available yet for this article.
November 29, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27907277/her2-testing-and-clinical-decision-making-in-gastroesophageal-adenocarcinoma-guideline-summary-from-the-college-of-american-pathologists-american-society-for-clinical-pathology-and-american-society-of-clinical-oncology
#2
Angela N Bartley, Mary Kay Washington, Nofisat Ismaila, Jaffer A Ajani
No abstract text is available yet for this article.
November 29, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27906454/immunotherapy-of-head-and-neck-cancer-emerging-clinical-trials-from-a-national-cancer-institute-head-and-neck-cancer-steering-committee-planning-meeting
#3
Julie E Bauman, Ezra Cohen, Robert L Ferris, David J Adelstein, David M Brizel, John A Ridge, Brian O'Sullivan, Barbara A Burtness, Lisa H Butterfield, William E Carson, Mary L Disis, Bernard A Fox, Thomas F Gajewski, Maura L Gillison, James W Hodge, Quynh-Thu Le, David Raben, Scott E Strome, Jean Lynn, Shakun Malik
Recent advances have permitted successful therapeutic targeting of the immune system in head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents are being rapidly adopted by the oncologic community and hold considerable promise. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how to further investigate the use of immunotherapy in patients with HNSCC. The goals of the meeting were to consider phase 2 or 3 trial designs primarily in 3 different patient populations: those with previously untreated, human papillomavirus-initiated oropharyngeal cancers; those with previously untreated, human papillomavirus-negative HNSCC; and those with recurrent/metastatic HNSCC...
December 1, 2016: Cancer
https://www.readbyqxmd.com/read/27903156/american-society-of-clinical-oncology-obesity-initiative-rationale-progress-and-future-directions
#4
Jennifer A Ligibel, Dana Wollins
Obesity is increasingly being linked to the risk of developing and dying from cancer. In recognition of the growing contribution of obesity to cancer risk and outcomes, ASCO made obesity and cancer one of its core initiatives in 2014. The goals of this initiative included raising awareness of the relationship between obesity and cancer, providing tools and resources to oncology providers and patients to help encourage conversations regarding weight management in cancer survivors, fostering a robust research agenda, and advocating for access to evidence-based weight management programs for cancer survivors...
December 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27900490/discordance-between-original-and-central-laboratories-in-er-and-her2-results-in-a-diverse-population-based-sample
#5
Jennifer J Griggs, Ann S Hamilton, Kendra L Schwartz, Weiqiang Zhao, Paul H Abrahamse, Dafydd G Thomas, Julie M Jorns, Rachel Jewell, Maria E Sibug Saber, Reina Haque, Steven J Katz
PURPOSE: To investigate the discordance between original and central laboratories in estrogen receptor (ER) status, in tumors originally deemed to be ER-negative, and in HER2 status in a diverse population-based sample. METHODS: In a follow-up study of 1785 women with Stage I-III breast cancer diagnosed between 2005 and 2007 in the Detroit and Los Angeles County SEER registry catchment areas, participants were asked to consent to reassessment of ER (in tumors originally deemed to be ER-negative) and HER2 status on archival tumor samples approximately four years after diagnosis...
November 29, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27898175/interventions-for-promoting-participation-in-shared-decision-making-for-children-with-cancer
#6
REVIEW
Imelda Coyne, Dónal P O'Mathúna, Faith Gibson, Linda Shields, Edith Leclercq, Greg Sheaf
BACKGROUND: This is an update of the Cochrane systematic review of shared decision-making (SMD) making published in 2013. Children's rights to have their views heard in matters that affect their lives are now well established since the publication of the UN Convention treaty (1989). Children with cancer generally prefer to be involved in decision-making and consider it important that they have the opportunity to take part in decision-making concerning their health care, even in end-of-life decisions...
November 29, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27894223/-oncology-medications-prescription-in-a-cancer-service-appropriateness-to-clinical-practice-guidelines
#7
Valeria Palchik, María Luz Traverso, Marisel Colautti, Mariela Bianchi, Lucía Dolza, José María Catena, Mercedes Salamano
OBJECTIVE: To assess prescription of oncology medications in municipal public health network of Rosario for its appropriateness to clinical practice guidelines. METHODS: Descriptive pharmacoepidemiological study in adult patients in an Oncology Service between January and June 2012. Compliance requirements with clinical practice guidelines were evaluated. RESULTS: 51.8% of diagnoses had at least one prescription medication that did not match recommendation by at least one of the guides considered...
November 1, 2016: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/27893929/a-review-of-cost-communication-in-oncology-patient-attitude-provider-acceptance-and-outcome-assessment
#8
REVIEW
Ya-Chen Tina Shih, Chun-Ru Chien
The American Society of Clinical Oncology released its first guidance statement on the cost of cancer care in August 2009, affirming that patient-physician cost communication is a critical component of high-quality care. This forward-thinking recommendation has grown increasingly important in oncology practice today as the high costs of cancer care impose tremendous financial burden to patients, their families, and the health care system. For the current review, a literature search was conducted using the PubMed and Web of Science databases to identify articles that covered 3 topics related to patient-physician cost communication: patient attitude, physician acceptance, and the associated outcomes; and 15 articles from 12 distinct studies were identified...
November 28, 2016: Cancer
https://www.readbyqxmd.com/read/27893329/reaffirming-and-clarifying-the-american-society-of-clinical-oncology-s-policy-statement-on-the-critical-role-of-phase-i-trials-in-cancer-research-and-treatment
#9
Jeffrey S Weber, Laura A Levit, Peter C Adamson, Suanna S Bruinooge, Howard A Burris, Michael A Carducci, Adam P Dicker, Mithat Gönen, Stephen M Keefe, Michael A Postow, Michael A Thompson, David M Waterhouse, Susan L Weiner, Lynn M Schuchter
No abstract text is available yet for this article.
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27893327/radiation-therapy-for-glioblastoma-american-society-of-clinical-oncology-clinical-practice-guideline-endorsement-of-the-american-society-for-radiation-oncology-guideline
#10
Erik P Sulman, Nofisat Ismaila, Terri S Armstrong, Christina Tsien, Tracy T Batchelor, Tim Cloughesy, Evanthia Galanis, Mark Gilbert, Vinai Gondi, Mary Lovely, Minesh Mehta, Matthew P Mumber, Andrew Sloan, Susan M Chang
Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy for glioblastoma. Because of its relevance to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies used to critically examine guidelines developed by other organizations. Methods The ASTRO guideline on radiation therapy for glioblastoma was reviewed for developmental rigor by methodologists. An ASCO endorsement panel updated the literature search and reviewed the content and recommendations...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27884041/follow-up-strategies-for-patients-treated-for-non-metastatic-colorectal-cancer
#11
REVIEW
Mark Jeffery, Brigid E Hickey, Phil N Hider, Adrienne M See
BACKGROUND: It is common clinical practice to follow patients with colorectal cancer (CRC) for several years following their curative surgery or adjuvant therapy, or both. Despite this widespread practice, there is considerable controversy about how often patients should be seen, what tests should be performed, and whether these varying strategies have any significant impact on patient outcomes. This is the second update of a Cochrane Review first published in 2002 and first updated in 2007...
November 24, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27868581/2016-updated-american-society-of-clinical-oncology-oncology-nursing-society-chemotherapy-administration-safety-standards-including-standards-for-pediatric-oncology
#12
Michael N Neuss, Terry R Gilmore, Kristin M Belderson, Amy L Billett, Tara Conti-Kalchik, Brittany E Harvey, Carolyn Hendricks, Kristine B LeFebvre, Pamela B Mangu, Kristen McNiff, MiKaela Olsen, Lisa Schulmeister, Ann Von Gehr, Martha Polovich
Purpose To update the ASCO/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards...
November 21, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27866194/efficacy-of-bevacizumab-in-the-first-line-treatment-of-patients-with-ras-mutations-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis
#13
Mingyi Zhou, Ping Yu, Jinglei Qu, Ying Chen, Yang Zhou, Lingyu Fu, Jingdong Zhang
BACKGROUND/AIMS: Whether patients with RAS mutation metastatic colorectal cancer (mCRC) obtain benefits from bevacizumab added to first-line chemotherapy remains unclear. METHODS: PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and the American Society of Clinical Oncology and European Society for Medical Oncology databases were searched to identify abstracts for randomized controlled trials (RCTs) evaluating the efficacy of bevacizumab for the first-line treatment of patients with RAS mutations mCRC from inception to the end of April 2016...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27864218/second-primary-malignancies-in-multiple-myeloma-an-overview-and-imwg-consensus
#14
REVIEW
P Musto, K C Anderson, M Attal, P G Richardson, A Badros, J Hou, R Comenzo, J Du, B G M Durie, J San Miguel, H Einsele, W M Chen, L Garderet, G Pietrantuono, J Hillengass, R A Kyle, P Moreau, J J Lahuerta, O Landgren, H Ludwig, A Larocca, A Mahindra, M Cavo, A Mazumder, P L McCarthy, A Nouel, S V Rajkumar, A Reiman, E R Serra, O Sezer, E Terpos, I Turesson, S Usmani, B M Weiss, A Palumbo
BACKGROUND: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27861753/screening-for-depression-in-cancer-patients-receiving-radiotherapy-feasibility-and-identification-of-effective-tools-in-the-nrg-oncology-rtog-0841-trial
#15
Lynne I Wagner, Stephanie L Pugh, William Small, Jeffrey Kirshner, Kulbir Sidhu, Martin J Bury, Albert S DeNittis, Tracy E Alpert, Binh Tran, Beatrice F Bloom, Julie Mai, Alexander Yeh, Kalika Sarma, Mark Becker, Jennifer James, Deborah Watkins Bruner
BACKGROUND: Brief tools are needed to screen oncology outpatients for depressive symptoms. METHODS: Patients starting radiotherapy for the first diagnosis of any tumor completed distress screening tools, including the 9-item Patient Health Questionnaire (PHQ-9), the 2-item Patient Health Questionnaire (PHQ-2), the National Comprehensive Cancer Network Distress Thermometer (NCCN-DT), and the Hopkins Symptom Checklist (HSCL) (25-item version). Patients exceeding validated cutoff scores and a systematic sample of patients whose screening was negative completed the Structured Clinical Interview for DSM-IV (SCID) mood disorder modules via telephone...
November 10, 2016: Cancer
https://www.readbyqxmd.com/read/27859010/bevacizumab-combined-with-capecitabine-and-oxaliplatin-in-patients-with-advanced-adenocarcinoma-of-the-small-bowel-or-ampulla-of-vater-a-single-center-open-label-phase-2-study
#16
Pat Gulhati, Kanwal Raghav, Rachna T Shroff, Gauri R Varadhachary, Scott Kopetz, Milind Javle, Wei Qiao, Huamin Wang, Jeffrey Morris, Robert A Wolff, Michael J Overman
BACKGROUND: Capecitabine with oxaliplatin (CAPOX) has previously demonstrated clinical activity in patients with small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC). Herein, the authors conducted a phase 2 trial to evaluate the benefit of adding bevacizumab to CAPOX. METHODS: In this phase 2, single-arm, single-center, open-label study, patients aged ≥18 years with untreated, advanced SBA or AAC were recruited. Patients received capecitabine at a dose of 750 mg/m(2) orally twice daily on days 1 to 14, oxaliplatin at a dose of 130 mg/m(2) intravenously on day 1, and bevacizumab at a dose of 7...
November 14, 2016: Cancer
https://www.readbyqxmd.com/read/27854104/new-practical-approaches-to-chemotherapy-induced-neuropathic-pain-prevention-assessment-and-treatment
#17
REVIEW
Neil Majithia, Charles L Loprinzi, Thomas J Smith
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most disabling and demoralizing problems that arise for cancer survivors. When investigating symptoms of numbness, tingling, or pain in the extremities, it is critical to determine whether the problem is neuropathic, somatic, or mixed. If the diagnosis is CIPN, it is important to weigh the potential benefits and harms of possible treatment options, and to devise an evidence-based multimodality treatment program. Such programs may include mixtures of opioid and nonopioid adjunctive medications, based on evidence from CIPN trials, and also extrapolation from trials in patients with other neuropathic pain syndromes-although such extrapolating must be done with caution, since other syndromes sometimes respond to agents that CIPN does not respond to...
November 15, 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27845871/secondary-prevention-of-cervical-cancer-american-society-of-clinical-oncology-resource-stratified-clinical-practice-guideline-summary
#18
Jose Jeronimo, Philip E Castle, Sarah Temin, Surendra S Shastri
No abstract text is available yet for this article.
November 15, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27845868/anxiety-culture-and-expectations-oncologist-perceived-factors-associated-with-use-of-nonrecommended-serum-tumor-marker-tests-for-surveillance-of-early-stage-breast-cancer
#19
Erin E Hahn, Corrine Munoz-Plaza, Jianjin Wang, Jazmine Garcia Delgadillo, Joanne E Schottinger, Brian S Mittman, Michael K Gould
PURPOSE: Breast cancer offers several opportunities for reducing use of ineffective practices based on American Society of Clinical Oncology guidelines. We assessed oncologist-perceived factors associated with use of one such practice-serum tumor markers for post-treatment breast cancer surveillance-focusing on medical oncologists with high, medium, or low test use. METHODS: Using a mixed-methods design, we identified patients who had been treated for early-stage breast cancer diagnosed between January 1, 2009, and December 31, 2012, within Kaiser Permanente Southern California and calculated the number of tests ordered from January 1, 2010, to December 31, 2014...
November 15, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27843641/esmo-asco-recommendations-for-a-global-curriculum-in-medical-oncology-edition-2016
#20
REVIEW
Christian Dittrich, Michael Kosty, Svetlana Jezdic, Doug Pyle, Rossana Berardi, Jonas Bergh, Nagi El-Saghir, Jean-Pierre Lotz, Pia Österlund, Nicholas Pavlidis, Gunta Purkalne, Ahmad Awada, Susana Banerjee, Smita Bhatia, Jan Bogaerts, Jan Buckner, Fatima Cardoso, Paolo Casali, Edward Chu, Julia Lee Close, Bertrand Coiffier, Roisin Connolly, Sarah Coupland, Luigi De Petris, Maria De Santis, Elisabeth G E de Vries, Don S Dizon, Jennifer Duff, Linda R Duska, Alexandru Eniu, Marc Ernstoff, Enriqueta Felip, Martin F Fey, Jill Gilbert, Nicolas Girard, Andor W J M Glaudemans, Priya K Gopalan, Axel Grothey, Stephen M Hahn, Diana Hanna, Christian Herold, Jørn Herrstedt, Krisztian Homicsko, Dennie V Jones, Lorenz Jost, Ulrich Keilholz, Saad Khan, Alexander Kiss, Claus-Henning Köhne, Rainer Kunstfeld, Heinz-Josef Lenz, Stuart Lichtman, Lisa Licitra, Thomas Lion, Saskia Litière, Lifang Liu, Patrick J Loehrer, Merry Jennifer Markham, Ben Markman, Marius Mayerhoefer, Johannes G Meran, Olivier Michielin, Elizabeth Charlotte Moser, Giannis Mountzios, Timothy Moynihan, Torsten Nielsen, Yuichiro Ohe, Kjell Öberg, Antonio Palumbo, Fedro Alessandro Peccatori, Michael Pfeilstöcker, Chandrajit Raut, Scot C Remick, Mark Robson, Piotr Rutkowski, Roberto Salgado, Lidia Schapira, Eva Schernhammer, Martin Schlumberger, Hans-Joachim Schmoll, Lowell Schnipper, Cristiana Sessa, Charles L Shapiro, Julie Steele, Cora N Sternberg, Friedrich Stiefel, Florian Strasser, Roger Stupp, Richard Sullivan, Josep Tabernero, Luzia Travado, Marcel Verheij, Emile Voest, Everett Vokes, Jamie Von Roenn, Jeffrey S Weber, Hans Wildiers, Yosef Yarden
The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of 64 ESMO-appointed and 32 ASCO-appointed authors. First published in 2004 and updated in 2010, the GC edition 2016 answers to the need for updated recommendations for the training of physicians in medical oncology by defining the standard to be fulfilled to qualify as medical oncologists. At times of internationalisation of healthcare and increased mobility of patients and physicians, the GC aims to provide state-of-the-art cancer care to all patients wherever they live...
2016: ESMO Open
keyword
keyword
77718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"